JP6710098B2 - Nutritional composition and dietary supplement - Google Patents

Nutritional composition and dietary supplement Download PDF

Info

Publication number
JP6710098B2
JP6710098B2 JP2016094504A JP2016094504A JP6710098B2 JP 6710098 B2 JP6710098 B2 JP 6710098B2 JP 2016094504 A JP2016094504 A JP 2016094504A JP 2016094504 A JP2016094504 A JP 2016094504A JP 6710098 B2 JP6710098 B2 JP 6710098B2
Authority
JP
Japan
Prior art keywords
arginine
salt
producing
amino acid
basic amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016094504A
Other languages
Japanese (ja)
Other versions
JP2017201906A (en
Inventor
潤 坪田
潤 坪田
松下 功
功 松下
拓 西村
拓 西村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Gas Co Ltd
Original Assignee
Osaka Gas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Gas Co Ltd filed Critical Osaka Gas Co Ltd
Priority to JP2016094504A priority Critical patent/JP6710098B2/en
Publication of JP2017201906A publication Critical patent/JP2017201906A/en
Application granted granted Critical
Publication of JP6710098B2 publication Critical patent/JP6710098B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Description

本発明は、栄養剤組成物及び栄養補助食品に関する。 The present invention relates to nutritional supplement compositions and dietary supplements.

3ヒドロキシ酪酸やその塩(以下3HBと称する、また、3HBと称する場合、特にその単量体を指すものとする)は、もともと人の体内に存在する物質であるため生体親和性が高く、糖質に代わる画期的なエネルギー源として期待されている。また、3HBは単なるエネルギー源という役割だけでなく、様々な遺伝子の発現やタンパク質の活性に影響するシグナル伝達物質としての作用があることがわかってきた。3HBは、例えば、遺伝子発現調節作用によって、ヒストン脱アセチル化酵素を阻害することによって認知機能や、長期持続記憶を改善することが知られ、アルツハイマーの予防に有効性が確認されている。例えば、ココナツオイルに多く含まれる中鎖脂肪酸の摂取および体内での代謝により生成される3HBが、脳や体内において糖質をうまく利用できないアルツハイマー病、糖尿病の患者の症状を改善させる効果を持つことが知られている。また、3HBは体内において糖質よりも速やかにエネルギーに変換されること、細胞への脂肪や糖の吸収を抑制する効果を有することから、アスリート向けのエネルギー物質、ダイエット・健康食品分野への応用が期待できる。 3-Hydroxybutyric acid and its salts (hereinafter referred to as 3HB, and when referred to as 3HB, particularly refer to its monomer) have a high biocompatibility since they are substances originally present in the human body, and sugar It is expected as an epoch-making energy source to replace quality. Further, it has been found that 3HB has not only a role as a simple energy source, but also an action as a signal transduction substance that affects the expression of various genes and the activity of proteins. 3HB is known to improve cognitive function and long-term persistent memory by inhibiting histone deacetylase by, for example, a gene expression regulatory action, and its effectiveness in the prevention of Alzheimer has been confirmed. For example, 3HB produced by ingestion of medium-chain fatty acid contained in coconut oil and metabolism in the body has an effect of improving symptoms in patients with Alzheimer's disease and diabetes who cannot utilize sugar efficiently in the brain and body. It has been known. In addition, 3HB is converted into energy faster than carbohydrates in the body, and has the effect of suppressing absorption of fats and sugars into cells. Therefore, 3HB is used as an energy substance for athletes and applied to the diet and health food fields. Can be expected.

このような3HBは、各種微生物にポリ3ヒドロキシ酪酸(以下PHBと称する)を生産させたのち、得られたPHBを酵素等により分解することにより得ることができる(特許文献1)。 Such 3HB can be obtained by causing various microorganisms to produce poly-3-hydroxybutyric acid (hereinafter referred to as PHB) and then decomposing the obtained PHB with an enzyme or the like (Patent Document 1).

また、3HBを人に投与可能な形態としては、3HBをオリゴマーとして静脈投与可能にすることが知られている(特許文献2)。 Further, as a form in which 3HB can be administered to humans, it is known that 3HB can be intravenously administered as an oligomer (Patent Document 2).

特開2010−168595号公報JP, 2010-168595, A 特開平06−321778号公報JP, 06-321778, A

しかし、3HBは、酸性であるため人が経口摂取するには抵抗が大きく、そのまま大量に摂取することは困難である。また、酸性度を低減すべく、金属塩として摂取することも考えられるが、このような場合、金属成分の過剰摂取が懸念され、特にナトリウム成分の取りすぎは、高血圧症や肝臓疾患等の原因となりうるので、経口摂取できたとしても大量摂取を避けたいものとなっている。
また、オリゴマーとして静脈投与する場合、経口投与に比べて侵襲性が高く、より一層人が摂取するのに抵抗が大きく、さらに、オリゴマーがアミノ酸塩とされているものの、オリゴマーが分解されつつ代謝される過程は非常に遅く、3HBのエネルギー変換についての即効性に欠けるため、用途が大きく限定されるという欠点があった。
However, since 3HB is acidic, it is difficult for humans to take orally, and it is difficult to take 3HB in large amounts. In addition, in order to reduce the acidity, it may be considered to be ingested as a metal salt, but in such a case, it is feared that the metal component is excessively ingested. In particular, too much sodium component is a cause of hypertension or liver disease. Therefore, even if it can be taken orally, it is desired to avoid taking large amounts.
In addition, when administered intravenously as an oligomer, it is more invasive than oral administration and more resistant to human intake.Although the oligomer is an amino acid salt, it is metabolized while being decomposed. The process is very slow and lacks immediate effect on the energy conversion of 3HB, so that there is a drawback that the use is greatly limited.

したがって、本発明は上記実状に鑑み、3HBを経口投与しやすく、かつ人体への悪影響を抑制し、即効性のある優良なエネルギー源として利用可能な形態で提供しうる栄養剤組成物および栄養補助食品を提供する点にある。 Therefore, in view of the above circumstances, the present invention is a nutritional composition and nutritional supplement that can be orally administered with 3HB, can suppress the adverse effects on the human body, and can be provided in a form that can be used as an excellent energy source with immediate effect. The point is to provide food.

上記目的を達成するための本発明の栄養剤組成物の製造方法の特徴構成は、3HB(3ヒドロキシ酪酸単量体)の塩基性アミノ酸塩を主成分として含有する栄養剤組成物の製造方法であって、
3HB(3ヒドロキシ酪酸単量体)生産性のハロモナス菌を原料液に添加し、好気発酵を行った後、中和剤としてアルギニンを用いて嫌気発酵を行って3HBのアルギニン誘導体塩を含む発酵液を生産する工程と、
前記発酵液から前記3HBのアルギニン誘導体塩を精製する工程と、
精製した前記3HBのアルギニン誘導体塩を含有させる工程とを行う点にある。
Characterizing feature of the method for manufacturing the nutraceutical compositions of the present invention for achieving the above object, the manufacturing method of the nutrient composition containing as a main component a basic amino acid salt of 3HB (3-hydroxybutyric acid monomer) There
3HB (3-hydroxybutyric acid monomer)-producing Halomonas bacterium is added to a raw material liquid, aerobically fermented, and then anaerobically fermented using arginine as a neutralizing agent to ferment containing an arginine derivative salt of 3HB. The process of producing liquid,
Purifying the arginine derivative salt of 3HB from the fermentation broth,
And the step of containing the purified arginine derivative salt of 3HB .

上記構成によると、栄養剤組成物の製造方法によって製造された3HBは、塩基性アミノ酸により中和された形態となっており、直接摂取しても酸味が少ないので、人が経口摂取するうえで大きな抵抗にはなりにくくなっている。また、金属塩ではないため、金属成分(たとえばナトリウム)の過剰摂取の問題もない。加えて、3HB塩基性アミノ酸塩が体内で分解されて生じる塩基性アミノ酸は人体に良好な効果を発揮することが知られているので、3HBと塩基性アミノ酸との両者の人体に対する効果をともに得られる点で好ましいと考えられる。また、この3HBの塩基性アミノ酸塩は、3ヒドロキシ酪酸の単量体(モノマー)と塩基性アミノ酸との塩であるから低分子量であり、オリゴマーやポリマーを用いるのに比べて、分解速度が比較的早く、経口摂取でも短時間で血中ケトン濃度が上昇しうることが実験的に明らかになっている。 According to the above configuration, 3HB produced by the method for producing a nutritional supplement composition is in a form neutralized with a basic amino acid and has a low sourness even when directly ingested, so that 3HB is orally ingested by humans. It is hard to become a big resistance. Further, since it is not a metal salt, there is no problem of excessive intake of metal components (for example, sodium). In addition, it is known that the basic amino acid produced by the decomposition of the 3HB basic amino acid salt in the body exerts a good effect on the human body. Therefore, both the effects of 3HB and the basic amino acid on the human body can be obtained. It is considered to be preferable in that it can be obtained. In addition, this basic amino acid salt of 3HB has a low molecular weight because it is a salt of a monomer (monomer) of 3hydroxybutyric acid and a basic amino acid, and its decomposition rate is higher than that of using an oligomer or polymer. It has been empirically revealed that blood ketone levels can be elevated in a short period of time even if taken orally.

塩基性アミノ酸による好ましい効果としては、たとえば、栄養剤組成物が3HBのアルギニン誘導体塩を主成分として含有する場合、血流改善効果などが期待できる。また、このような塩基性アミノ酸自体、高pHであるため、経口摂取するには抵抗が大きいものの、3HBの塩とすることで、お互いに相乗的に摂取抵抗を抑制できる利点もある。 As a preferable effect of the basic amino acid, for example, when the nutritional supplement composition contains 3HB arginine derivative salt as a main component, a blood flow improving effect and the like can be expected. Further, since such a basic amino acid itself has a high pH, it is highly resistant to oral ingestion, but the salt of 3HB has an advantage that it can synergistically suppress the ingestion resistance.

塩基性アミノ酸としてのアルギニン誘導体としては、アルギニン、シトルリンが挙げられ、他に塩基性アミノ酸として、ヒスチジン、リシン等が挙げられる。 Examples of the arginine derivative as the basic amino acid include arginine and citrulline, and examples of the basic amino acid include histidine and lysine.

したがって、本発明の栄養剤組成物の製造方法によって製造された栄養剤組成物は、即効性のある優良なエネルギー源として利用可能であるとともに、十分量の経口摂取が容易なものとなっている。そのため、粉末、顆粒、錠剤、タブレット、等の健康補助食品や、クッキー、ビスケット、グミ、チョコレート、ガムなどの機能性食品等に例示される栄養補助食品として3HBを含有させて利用することができ、3HBの利用可能性を大きく高めることができる。 Therefore, the nutritional supplement composition produced by the method for producing a nutritional supplement composition of the present invention can be used as a quick-acting and excellent energy source, and can be easily orally ingested in a sufficient amount. .. Therefore, 3HB can be used by including 3HB as a dietary supplement such as powders, granules, tablets, tablets, and the like, and functional foods such as cookies, biscuits, gummi, chocolate, gum, and the like. The availability of 3HB can be greatly increased.

経口摂取試験の結果を示すグラフGraph showing the results of the oral intake test

以下に、本発明の実施形態にかかる栄養剤組成物及び栄養補助食品を説明する。尚、以下に好適な実施形態を記すが、これら実施形態はそれぞれ、本発明をより具体的に例示するために記載されたものであって、本発明の趣旨を逸脱しない範囲において種々変更が可能であり、本発明は、以下の記載に限定されるものではない。 Hereinafter, the nutritional supplement composition and the dietary supplement according to the embodiment of the present invention will be described. The preferred embodiments will be described below, but these embodiments are described for more specifically illustrating the present invention, and various modifications can be made without departing from the spirit of the present invention. However, the present invention is not limited to the following description.

〔3HB〕
3HBは、3HB生産性のハロモナス菌を添加した発酵プロセスを行い、得られた発酵液からハロモナス菌を分離除去し、精製することにより得られる。発酵プロセスは、果汁等の糖質栄養源を含有する原料液に、3HB生産性のハロモナス菌をそのまま添加し、好気発酵、嫌気発酵を順に行うプロセス(特開2013−081403号公報等参照)として実施することができる。これにより、糖質が3HBに変換され、発酵液中に生産されることになる。
[3HB]
3HB is obtained by performing a fermentation process in which a 3HB-producing Halomonas bacterium is added, separating and removing Halomonas bacterium from the obtained fermentation liquor, and purifying. The fermentation process is a process in which a 3HB-producing Halomonas bacterium is added as it is to a raw material liquid containing a sugar nutrient such as fruit juice, and aerobic fermentation and anaerobic fermentation are sequentially performed (see JP 2013-081403 A, etc.). Can be implemented as. As a result, the sugar is converted to 3HB and produced in the fermentation broth.

〔3HBアルギニン塩〕
3HBの塩基性アミノ酸塩としての3HBアルギニン塩(3HBのアルギニン誘導体塩の一例)は、上記3HBの生成プロセスにおける嫌気発酵の工程において、3HBの生成とともにpHの低下する発酵液を中和する中和剤として、アルギニンを用いることにより3HBアルギニン塩の形で溶解した発酵液として生産することができる(嫌気発酵の工程はアルカリ性での嫌気発酵4〜8時間で終了)。発酵液は、膜分離により菌体を除去することで約10%の3HBアルギニン塩を含有する上清が分離され、この上清から溶媒を留去することにより、粉末状の3HBアルギニン塩として精製される。または、3HBの生成とともにpHの低下する発酵液を中和する中和剤として水酸化カルシウムを用い、嫌気発酵後に膜分離により菌体を除去したのちに、硫酸を添加してカルシウムを硫酸カルシウム塩として沈殿除去したものに、アルギニンを添加、溶媒を留去することにより、粉末状の3HBアルギニン塩として精製される。
[3HB arginine salt]
The 3HB arginine salt (an example of an arginine derivative salt of 3HB) as a basic amino acid salt of 3HB is a neutralizing agent that neutralizes a fermentation solution whose pH decreases with the production of 3HB in the anaerobic fermentation step in the above 3HB production process. By using arginine as an agent, it can be produced as a fermentation liquor dissolved in the form of 3HB arginine salt (the anaerobic fermentation process is completed in 4 to 8 hours in anaerobic fermentation in alkaline condition). The fermentation liquor is separated into a supernatant containing about 10% 3HB arginine salt by removing the cells by membrane separation, and the solvent is distilled off from the supernatant to purify it as a powdery 3HB arginine salt. To be done. Alternatively, calcium hydroxide is used as a neutralizing agent for neutralizing a fermented liquor whose pH decreases with the production of 3HB, and after removing bacterial cells by membrane separation after anaerobic fermentation, sulfuric acid is added to the calcium sulfate calcium sulfate salt. After the precipitation is removed, arginine is added, and the solvent is distilled off, whereby the powdery 3HB arginine salt is purified.

〔栄養剤組成物〕
本実施形態にかかる栄養剤組成物は、得られた粉末状の3HBアルギニン塩をそのまま錠剤化して、栄養剤組成物あるいは、栄養剤組成物を含有する栄養補助食品として提供することができる。また、錠剤化にあたっては、調剤用助剤等の他の成分の添加を妨げるものではない。また栄養補助食品として提供する場合には、小麦粉、砂糖などの他の食品成分とともに加工して、クッキー、ビスケット、グミ、チョコレート、ガムなどの形態とすることができる。
[Nutrient composition]
The nutritional supplement composition according to the present embodiment can be provided as a nutritional supplement composition or a dietary supplement containing the nutritional supplement composition by tableting the obtained powdery 3HB arginine salt as it is. In addition, tableting does not prevent addition of other components such as an auxiliary agent for preparation. When it is provided as a dietary supplement, it can be processed with other food ingredients such as wheat flour and sugar to be in the form of cookies, biscuits, gummi, chocolate, gum and the like.

〔経口摂取試験〕
60kgの体重あたり15gとなるように換算して、モニタとなる人に3HBアルギニン塩を食前に経口摂取して、継時的に血中の3HB濃度を計測した。その結果、図1に示すように、30分後には0.6mM、45分後には1mMに達し、経口摂取で短時間で3HBの血中濃度が上昇した。特許文献2では、ラット血中で30分後に700μmol/Lに達したが、ヒトに換算すると120分後に相当し、血中濃度の上昇に時間がかかるのに対し、非常に素早く血中濃度が上昇し即効性が高いことが分かった。
[Oral intake test]
It was converted to 15 g per 60 kg of body weight, and the person serving as a monitor was orally ingested with 3HB arginine salt before meals, and the 3HB concentration in blood was continuously measured. As a result, as shown in FIG. 1, it reached 0.6 mM after 30 minutes and reached 1 mM after 45 minutes, and the blood concentration of 3HB increased in a short time after oral intake. In Patent Document 2, it reached 700 μmol/L in rat blood after 30 minutes, but it corresponds to 120 minutes after conversion into human, and it takes time to increase the blood concentration, but the blood concentration is very quick. It turned out to be high and the immediate effect was high.

〔官能試験〕
(方法)
アルギニン(市販品)、3HB(精製品)、3HBアルギニン塩(上記実施例)について、それぞれ苦み、酸味および旨みに関して順位法(酸味、苦み、旨みが少ないと感じたのが1、また苦み、酸味、旨みが多いと感じたものが4の4段階表示)で評価し、比較した。3HBは、pH調整に従来通りNaOHを用いて最終3HBNa塩として回収したものを、電気透析、イオン交換により脱塩して精製し、単離したものを使用した。
アルギニン、3HB、3HBアルギニン塩を各100mg秤量し1mlの水に溶解して、各パネラーにより苦み、酸味および旨みについてそれぞれ官能試験を実施した。
[Sensory test]
(Method)
Arginine (commercially available product), 3HB (purified product), and 3HB arginine salt (the above-mentioned example) were ranked in terms of bitterness, sourness, and taste (sourness, bitterness, and taste were less than 1; However, the ones that were felt to have a lot of taste were evaluated and compared according to 4 scale of 4). As 3HB, what was recovered as the final 3HBNa salt using NaOH as usual for pH adjustment, desalted by electrodialysis and ion exchange, purified, and isolated was used.
100 mg each of arginine, 3HB and 3HB arginine salt was weighed and dissolved in 1 ml of water, and each panelist conducted a sensory test for bitterness, sourness and umami.

(結果)
表1(苦み)、表2(酸味)、表3(旨み)に関する官能試験結果を示す。表1、表2、表3の結果をもとに苦み、酸味、旨みの評価を実施した。アルギニンは酸味が無いが苦みが高く、一方3HBは苦みが無いが酸味が高い結果が得られた。しかし、3HBアルギニン塩は酸味、苦みを感じず、旨みを感じる結果が得られ、明らかな有意差が認められ、手軽に食べられることがわかった。
(result)
The sensory test results regarding Table 1 (bitterness), Table 2 (sourness), and Table 3 (umami) are shown. The bitterness, sourness, and umami were evaluated based on the results of Table 1, Table 2, and Table 3. Arginine has no sourness but high bitterness, while 3HB has no bitterness but high sourness. However, it was found that 3HB arginine salt was not sour and bitter, but the taste was delicious, and there was a clear significant difference, making it easy to eat.

Figure 0006710098
Figure 0006710098

Figure 0006710098
Figure 0006710098

Figure 0006710098
Figure 0006710098

また、3HBはアルツハイマーの予防、癌の予防、アスリート向けのエネルギー物質として有効性が認められているが、現在は3HB塩もしくはエステルとして摂取する必要がある。3HBの金属塩では、金属成分の取りすぎになるし、エステルは製造プロセスが複雑でありまた体内での酵素分解が必要で即効性に乏しい。本発明では、アミノ酸塩として摂取できることから、金属成分(特にナトリウム)の取り過ぎが無く、摂取し易い。また、体内で3HBとアミノ酸に分かれてそれぞれ効果が期待できる。例えば、塩基性アミノ酸のアルギニンは、血流向上機能がある。
さらに、アルギニンは、摂取すると一酸化窒素が増えて、血管を拡張させる作用が知られている。一酸化窒素は、活性酸素が存在すると活性酸素の還元に使われ、その効果が消失するため、アルギニンを摂取する場合は、抗酸化剤(還元剤)との同時接種が好ましい。
また、3HBは体内ではアセト酢酸に変換するが、その際に補酵素のNADを必要とし、NADHができる。NADHは還元力があり、3HBアルギニンとして摂取することで、アルギニンの酸化を抑制し、アルギニン単体よりも、血管拡張効果を高めることが可能となり相乗効果があると考えられる。
Further, 3HB has been confirmed to be effective as an energy substance for prevention of Alzheimer's disease, prevention of cancer, and athletes, but it is necessary to ingest it now as 3HB salt or ester. The metal salt of 3HB has too much metal component, and the ester has a complicated manufacturing process and requires enzymatic decomposition in the body, and thus has poor immediate effect. In the present invention, since it can be ingested as an amino acid salt, it is easy to ingest without excessive intake of metal components (particularly sodium). In addition, 3HB and amino acid are divided in the body, and each effect can be expected. For example, the basic amino acid arginine has a blood flow improving function.
In addition, arginine is known to increase the amount of nitric oxide when ingested, thereby expanding blood vessels. Nitric oxide is used for reducing active oxygen in the presence of active oxygen, and its effect disappears. Therefore, when ingesting arginine, simultaneous inoculation with an antioxidant (reducing agent) is preferable.
In addition, 3HB is converted into acetoacetic acid in the body, but in that case, NAD, which is a coenzyme, is required, and NADH is formed. NADH has a reducing power, and when ingested as 3HB arginine, it suppresses the oxidation of arginine and can enhance the vasodilatory effect as compared with arginine alone, and is considered to have a synergistic effect.

〔別実施形態〕
下記の別実施形態は、矛盾が生じない限り、複数を組み合わせて上記実施形態に適用できる。なお、本発明の範囲は、これら実施形態に限定されるものではない。
[Another embodiment]
As long as no contradiction arises, a plurality of the following other embodiments can be combined and applied to the above embodiments. The scope of the present invention is not limited to these embodiments.

(1)
上記実施形態においては、3HBの発酵プロセスによる製造過程で中和剤としてアルギニンを用いることでアルギニン塩を製造したが、これに限らず、精製された3HBをアルギニンと反応させて3HBアルギニンとすることもできるし、中和剤として水酸化カルシウムを用いて3HBカルシウム塩とした後、アルギニン硫酸塩を反応させて3HBアルギニンを得ることもできる。いずれも簡便な方法で3HBアルギニンを製造することができ好ましい。
(1)
In the above embodiment, the arginine salt was produced by using arginine as the neutralizing agent in the production process of the 3HB fermentation process, but the present invention is not limited to this, and purified 3HB is reacted with arginine to form 3HB arginine. Alternatively, it is possible to obtain 3HB arginine by reacting arginine sulfate with 3HB calcium salt using calcium hydroxide as a neutralizing agent. Both are preferable because 3HB arginine can be produced by a simple method.

また、上述の例では3HBアルギニンを例示したが、他の塩基性アミノ酸塩であってもよく、このような場合、上述の実施の形態におけるアルギニンに代えて、他の塩基性アミノ酸としてのシトルリン、ヒスチジン、リシンを用いることで、3HBシトルリン、3HBヒスチジン、3HBリシンが得られることは明らかである。これらは、3HBアルギニンと同様に、3HBの酸性度が緩和されるとともに、経口摂取するうえでの抵抗となりにくくなり、また、3HBと、シトルリン、ヒスチジン、リシンそれぞれの固有の効果を同時に発現させられる効果が期待される。 Further, in the above example, 3HB arginine was illustrated, but other basic amino acid salts may be used, and in such a case, instead of arginine in the above-mentioned embodiment, citrulline as another basic amino acid, It is clear that 3HB citrulline, 3HB histidine and 3HB lysine can be obtained by using histidine and lysine. Similar to 3HB arginine, these alleviate the acidity of 3HB and are less likely to resist oral ingestion, and can simultaneously exhibit the unique effects of 3HB and citrulline, histidine, and lysine. Expected to be effective.

本発明の栄養剤組成物は、即効性のある優良なエネルギー源として利用可能であるとともに、経口摂取容易なものとなっているので、粉末、顆粒、錠剤、タブレット、等の健康補助食品や、クッキー、ビスケット、グミ、チョコレート、ガムなどの機能性食品等に例示される栄養補助食品に含有させて利用することができ、3HBの利用可能性を大きく高めることができる。 The nutritional supplement composition of the present invention can be used as a good energy source with immediate effect, and since it is easily ingested, health supplements such as powder, granules, tablets, tablets, and the like, It can be used by including it in nutritional supplements such as functional foods such as cookies, biscuits, gummies, chocolates and gums, and can greatly increase the availability of 3HB.

Claims (2)

3HB(3ヒドロキシ酪酸単量体)の塩基性アミノ酸塩を主成分として含有する栄養剤組成物の製造方法であって、
3HB(3ヒドロキシ酪酸単量体)生産性のハロモナス菌を原料液に添加し、好気発酵を行った後、中和剤としてアルギニンを用いて嫌気発酵を行って3HBのアルギニン誘導体塩を含む発酵液を生産する工程と、
前記発酵液から前記3HBのアルギニン誘導体塩を精製する工程と、
精製した前記3HBのアルギニン誘導体塩を含有させる工程とを行う、栄養剤組成物の製造方法
A method for producing a nutritional supplement composition containing a basic amino acid salt of 3HB (3 hydroxybutyric acid monomer) as a main component ,
3HB (3-hydroxybutyric acid monomer)-producing Halomonas bacterium is added to a raw material liquid, aerobically fermented, and then anaerobically fermented using arginine as a neutralizing agent to ferment containing an arginine derivative salt of 3HB. A process of producing liquid,
Purifying the arginine derivative salt of 3HB from the fermentation broth,
And a step of containing the purified arginine derivative salt of 3HB .
請求項1記載の栄養剤組成物の製造方法により製造した栄養剤組成物を含有させる工程を行う、栄養補助食品の製造方法 A step of incorporating the nutrient composition prepared by the method of claim 1 Symbol placement of nutritional compositions, method for producing a dietary supplement.
JP2016094504A 2016-05-10 2016-05-10 Nutritional composition and dietary supplement Active JP6710098B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016094504A JP6710098B2 (en) 2016-05-10 2016-05-10 Nutritional composition and dietary supplement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016094504A JP6710098B2 (en) 2016-05-10 2016-05-10 Nutritional composition and dietary supplement

Publications (2)

Publication Number Publication Date
JP2017201906A JP2017201906A (en) 2017-11-16
JP6710098B2 true JP6710098B2 (en) 2020-06-17

Family

ID=60321199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016094504A Active JP6710098B2 (en) 2016-05-10 2016-05-10 Nutritional composition and dietary supplement

Country Status (1)

Country Link
JP (1) JP6710098B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6945469B2 (en) * 2018-02-20 2021-10-06 大阪瓦斯株式会社 Method for producing acetoacetic acid
JP6991092B2 (en) * 2018-03-29 2022-01-12 大阪瓦斯株式会社 Sleep quality improver
JP2021185799A (en) * 2020-05-28 2021-12-13 大阪瓦斯株式会社 3-hydroxybutyric acid-containing fat composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521857B1 (en) * 1982-02-23 1985-10-31 Solvay PHARMACEUTICAL COMPOSITIONS CONTAINING 3-HYDROXYBUTANOIC ACID OR A SALT DERIVATIVE THEREOF AND SALTS DERIVED FROM 3-HYDROXYBUTANOIC ACID AND AN ORGANIC NITROGEN BASE
CA1334575C (en) * 1988-07-26 1995-02-28 Atsushi Hiraide Substitution fluid preparation comprising 3-hydroxybutyric acid (beta-hydroxybutyric acid) and its salts
JPH0733653A (en) * 1993-06-25 1995-02-03 Suntory Ltd Suppressor for aldehydic toxicity
CN1315473C (en) * 1997-03-17 2007-05-16 英国技术集团国际有限公司 Therapeutic compositions

Also Published As

Publication number Publication date
JP2017201906A (en) 2017-11-16

Similar Documents

Publication Publication Date Title
AU2009283171B2 (en) Hydroxybutyrate ester and medical use thereof
JP6275931B1 (en) Intestinal butyric acid increasing agent and butyric acid-producing bacteria proliferating agent
EP2271367B1 (en) Mineral absorption accelerator and iron deficiency anemia improver or food composition
JP6710098B2 (en) Nutritional composition and dietary supplement
JP2008063277A (en) Antioxidative composition for dieting
JP2019172642A (en) Sleep quality improver
KR20160013069A (en) Compositions comprising a mixture of bacteria comprising pediococcus and lactobacillus and methods for decreasing the effects of alcohols
JP6301024B2 (en) Felicaribacterium spp.
JP2008143811A (en) Lipid metabolism promoting composition
JP2007290969A (en) Anti-stress composition
WO2002100393A1 (en) Compositions for ameliorating attention-deficient/hyperactivity disorder
JP6571298B2 (en) Glycemic spike inhibitor, food, and method for producing blood glucose spike inhibitor
KR101540004B1 (en) Composition of Health Functional Foods for Improving of Blood sugar, Blood pressure, Blood Circulation and Cholesterol into Blood
JP2023154540A (en) Composition for preventing or improving age-related hearing loss
JP5222299B2 (en) Fat absorption inhibiting composition
JP2008074734A (en) Ameliorating agent for insulin resistance
JP7011347B2 (en) A composition for relieving a hangover or a composition for preventing, ameliorating or treating alcoholic liver disease containing beta-glucan as an active ingredient.
JP7069531B2 (en) Capsules containing pyrroloquinoline quinone or a salt thereof and branched chain amino acids
JP2005082495A (en) Cerebral cell-protecting composition
JP6025538B2 (en) Branched-chain amino acid degradation odor inhibitor and degradation odor control method
KR20190086876A (en) Food composition for diet comprising l-carnitine and coenzyme q10 as an active ingredient
KR20140076312A (en) Red pepper paste having hizikia fusiforme ferment-extract and manufacturing method thereof
EP3880650B1 (en) Method for producing lipids containing structural units on the basis of glycerides of hydroxy carboxylic acids
JP2004292355A (en) Anti-stress agent
JP4772295B2 (en) Exercise capacity improver containing conjugated fatty acid as an active ingredient

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200526

R150 Certificate of patent or registration of utility model

Ref document number: 6710098

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150